Joe Jimenez
Co-Founder and Managing Director @ Aditum Bio
Oakland, United States
Joe Jimenez is a Series A investor at Aditum Bio in Oakland focused on Life Science and Biotechnology. Joe Jimenez is the Co-Founder and Managing Director at Aditum Bio. Joe Jimenez attended Haas School of Business, University of California, Berkeley .
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Joe Jimenez invests in
Stages Joe Jimenez invests in
Countries Joe Jimenez invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Therapeutics 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, andrhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well. | $20M / Series A / Sep 07, 2021 | ||
| Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistentlyand potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters. | $70M / Series A / Aug 31, 2021 |
Co-Investors
About Aditum Bio
Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.
Aditum Bio Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Joe Jimenez
Co-Founder and Managing Director
|
|||
Ilan Zipkin
Partner and VP, Business Development and Licensing
|
|||
|
Mark Fishman
Co-Founder and Chair of the Scientific Advisory BoardAditum Bio
|
|||
Susie Phillips
Executive Assistant to Co-Founder and Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Joe Jimenez invest in?
Joe Jimenez invests primarily in Life Science, Biotechnology and Medical startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joe Jimenez?
Public channels for Joe Jimenez include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joe Jimenez last invest?
The most recent investment recorded for Joe Jimenez closed in Sep 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
